Liverpool HEP Interactions

Based on drug interaction studies conducted with Epclusa, no clinically significant drug interactions have been observed with raltegravir. Coadministration of raltegravir (400 mg twice daily with emtricitabine and tenofovir-DF) and sofosbuvir/velpatasvir (400/100 mg once daily) was studied in 30 subjects. Raltegravir Cmax increased by 3%, but AUC and Cmin decreased by 3% and 21%. No effect on the pharmacokinetic parameters of sofosbuvir, GS-331007 or velpatasvir was observed with raltegravir.

Epclusa Prescribing Information, Gilead Science Inc., June 2021.

Coadministration of sofosbuvir/velpatasvir (400/100 mg, once daily) with raltegravir (400 mg, twice daily) and emtricitabine/tenofovir-DF (200/300 mg, once daily) was studied in 30 healthy volunteers. Sofosbuvir AUC and Cmax increased by 24% and 1%, respectively. GS-331007 AUC and Ctau increased by 3% and 8%, while Cmax decreased by 5%. Velpatasvir AUC, Cmax, and Ctau decreased by 2%, 3%, and 3%, respectively. No dosage adjustments are required.

Drug-Drug Interaction Studies Between Hepatitis C Virus Antivirals Sofosbuvir/Velpatasvir and Boosted and Unboosted Human Immunodeficiency Virus Antiretroviral Regimens in Healthy Volunteers. Mogalian E, Stamm L M, Osinusi A et al. Clin Infect Dis, 2018; 67(6): 934-940.